Jefferies Financial Group Reaffirms “Buy” Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “buy” rating restated by Jefferies Financial Group in a note issued to investors on Tuesday, Digital Look reports. They currently have a GBX 2,500 price objective on the stock. Jefferies Financial Group‘s price objective would indicate a potential upside of 32.10% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Berenberg Bank boosted their price target on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research report on Tuesday, September 15th. Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 1,975 price target on shares of GSK in a report on Tuesday, September 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 2,000 price target on shares of GSK in a research report on Tuesday, September 29th. Two equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of GBX 2,064.38.

GSK Stock Down 1.1%

Shares of GSK opened at GBX 1,892.50 on Tuesday. The firm has a market capitalization of £75.83 billion, a P/E ratio of 16.07, a P/E/G ratio of 1.24 and a beta of 0.29. GSK has a 52 week low of GBX 1,592 and a 52 week high of GBX 2,282. The company has a 50-day simple moving average of GBX 1,846.47 and a 200-day simple moving average of GBX 1,918.77. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82.

GSK (LON:GSK) last issued its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. On average, equities research analysts expect that GSK will post 175.98 earnings per share for the current year.

Insider Activity

In other GSK news, insider Jonathan Symonds bought 1,500 shares of the company’s stock in a transaction on Friday, September 18th. The stock was acquired at an average price of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal acquired 637 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The shares were acquired at an average price of GBX 4,985 per share, with a total value of £31,754.45. Insiders have purchased a total of 2,151 shares of company stock worth $6,021,921 over the last quarter. 0.20% of the stock is currently owned by insiders.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: FDA approves Hibsago for chronic hepatitis B: GSK and Ionis Pharmaceuticals received U.S. approval for bepirovirsen, marketed as Hibsago, described as a first-of-its-kind treatment that may deliver a “functional cure” by helping control the virus after treatment ends. The approval creates a new commercial opportunity in a large, underserved market and is the primary reason investor sentiment has improved. GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cure
• Positive Sentiment: Analyst support remains intact: Jefferies reaffirmed its “Buy” rating on GSK, signaling continued confidence in the company’s valuation, pipeline and earnings outlook. GSK Stock Rating Reaffirmed as Buy by Jefferies Financial Group
• Positive Sentiment: Manufacturing investment planned in Pennsylvania: GSK plans to open a biopharmaceutical manufacturing facility in Pennsylvania, expanding U.S. production capacity and potentially supporting supply-chain resilience, jobs and future product launches. The investment may require substantial near-term capital spending. GSK Plans to Open Biopharmaceutical Manufacturing Facility in Pennsylvania
• Positive Sentiment: Commercial and pipeline partnerships expanded: GSK entered a UAE partnership to broaden access to its general medicines, while Hutchmed completed a licensing deal involving a KRAS-EGFR cancer therapy. These agreements could expand geographic reach and add to GSK’s oncology pipeline, although their financial impact was not detailed. Mubadala Bio’s IDS and GSK Strategic Partnership Hutchmed Closes GSK License Deal for KRAS-EGFR Cancer Therapy
• Negative Sentiment: Next-generation hepatitis B trial discontinued: GSK reportedly scrapped a trial of a newer hepatitis B therapy. While Hibsago’s approval is a major positive, ending a follow-on program narrows the longer-term pipeline and could limit future improvements or lifecycle extensions in the disease area. GSK Scraps Trial of Next-Generation Hepatitis B Therapy

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.